# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Com...
Brookline Capital analyst Tyler Bussian initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Ta...
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their conf...
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.51) by 5....
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...
Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranch...